Compare XPRO & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XPRO | ANIP |
|---|---|---|
| Founded | 1938 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2013 | 1999 |
| Metric | XPRO | ANIP |
|---|---|---|
| Price | $18.31 | $75.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $14.00 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 1.0M | 357.8K |
| Earning Date | 05-19-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.45 | ★ 2.15 |
| Revenue | ★ $522,493,000.00 | $206,547,000.00 |
| Revenue This Year | N/A | $44.10 |
| Revenue Next Year | $1.72 | $13.18 |
| P/E Ratio | $39.53 | ★ $36.17 |
| Revenue Growth | ★ 14.89 | 2.47 |
| 52 Week Low | $6.70 | $54.10 |
| 52 Week High | $18.38 | $99.50 |
| Indicator | XPRO | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 69.52 | 35.82 |
| Support Level | $12.18 | $62.89 |
| Resistance Level | N/A | $77.00 |
| Average True Range (ATR) | 0.96 | 2.65 |
| MACD | 0.12 | -0.34 |
| Stochastic Oscillator | 85.39 | 2.16 |
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.